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Background
Glutamine is the most abundant, free amino acid in plasma, 
utilized by cancer cells for survival and rapid reproduction. 
Cancer cells employ glutamine through a transporter (ASCT2)  
and metabolizing it through a catalyzing enzyme. During 
glutaminolysis, the amino acid transporter, SLC1A5 (ASCT2), 
metabolizes glutamine with a catalyzing enzyme
V-9302 treatment in-vivo
• Mice with with Cre/+; Kras/+; Smad4 -/- were divided into 
three groups:
Group 1 (low dose) consisted of 2 male mice and 2 female 
mice. 
Group 2 (control) consisted of 2 male mice.
Group 3 (high dose) consisted of 2 male mice and 2 female 
mice.
• Mice were given intraperitoneal injection of V-9302: 
Group 1 – V9302, 12.5mg/kg, twice a day for 4 weeks
Group 2 – Vehicle, 2% DMSO, twice a day for 4 weeks
Group 3 – V9302, 75mg/kg, single dose for 4 hours
Materials and methods





Mouse using the developed 
inhibitor of the ASCT2 amino acid 
transporter, V-9302, malignant 
tumors will be unable to 
metabolize glutamine leading to 
difficulties in proliferation and an 
imbalance of metabolites in the 
microenvironment.
Fig. 2 Breeding and genotyping. A. Mice with Cre/+;Kras/+;Smad4f/f are the only ones that 
will grow tumor with only a 25% chance of occurring. B. Genotyping through gel electrophoresis 
allows for the identification of the groups in the study. 
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Materials and methods (cont.)
Tumor tissue collection 
• Mice were euthanized after treatment. Tumors were extracted, 
half of the tissue was preserved in 10% formalin for 
histological analysis, the other half was flash frozen in liquid 
nitrogen for 1HNMR assay. Mice were 11 weeks old at 
dissection in group 1 (A) and 2 (B), and 9 weeks old in group 
3 (C).
Nuclear Magnetic Resonance (NMR)
• Generally utilized to determine the content, molecular 
structure, and purity of a sample. Allowed us to gather 
information on the metabolites in the tumor 
microenvironment. 
• Prepared the sample through derivatization and buffering 
before following usual NMR protocol. 
Hematoxylin and eosin staining
• Slides were prepared by preserving, staining, dehydration, 
infiltration, embedding, mirotoming, and mounting. 
Conclusions
• This investigation attempted to treat malignant cancer 
cells with V-9302 in different ways and found some 
changes in metabolic profile. 
• It is possible that interference with inhibiting glutamine 
transporter changes cancer characteristics. 
• However, it is essential to gain a better understanding of 
glutaminolysis as well as other cancer metabolisms 
before determining the most effective usage of V-9302 
and what manipulations can improve its benefits in 
treating cancer.  
Fig. 6 Representation of general results and takeaways of V-9302 treatment. V-9302 was able to 
inhibit glutaminolysis and thus decreases were noticed in lactate, glutamine, glutamate, choline, and 
acetate. 
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Fig. 3 Photographs of extracted tumor tissues. A. Group 1. B. Group 2 C. Group 3
Results
Nuclear Magnetic Resonance (NMR)
Group 1 Group 2 Group 3
Fig. 5 Histology of cancer cells (2.5x magnification). Darker purple represents healthy 
pancreatic cells, lighter purple is fibrosis, and white areas inside the area of the tumor are 
necrosis. 
Fig. 4 Measurement of Metabolites by Nuclear Magnetic Resonance (NMR). A. Glutamine, 




































































































































































• After treatment, the metabolism profile changed.
• NMR showed lower levels of glutamine, glutamate, and 
total choline in treated mice compared to the control group. 
• Lactate was lower at elevated doses of V9302.
• Acetate displayed lower levels in group 3 while group 1 saw 
no change.
Histology
• Histologically, chronic exposure of V9302 led to tumors that 
were less advanced than tumors from the acute dose control 
groups.
